Rabbit Polyclonal IL-2 antibody - conjugated to Biotin. Suitable for WB, sELISA and reacts with Recombinant fragment - Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human IL2 aa 1 to C-terminus.
Constituents: PBS, 0.1% BSA
WB | sELISA | |
---|---|---|
Recombinant fragment - Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info 0.10000-0.20000 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance (PubMed:6438535). Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RG) (PubMed:16293754, PubMed:16477002). Interaction with the receptor leads to oligomerization and conformation changes in the IL-2R subunits resulting in downstream signaling starting with phosphorylation of JAK1 and JAK3 (PubMed:7973659). In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5 (PubMed:8580378). This process leads to activation of several pathways including STAT, phosphoinositide-3-kinase/PI3K and mitogen-activated protein kinase/MAPK pathways (PubMed:25142963). Functions as a T-cell growth factor and can increase NK-cell cytolytic activity as well (PubMed:6608729). Promotes strong proliferation of activated B-cells and subsequently immunoglobulin production (PubMed:6438535). Plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T-cells, which are required for the maintenance of immune tolerance. Moreover, participates in the differentiation and homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as well as memory CD8-positive T-cells.
Interleukin-2, IL-2, T-cell growth factor, TCGF, IL2
Rabbit Polyclonal IL-2 antibody - conjugated to Biotin. Suitable for WB, sELISA and reacts with Recombinant fragment - Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human IL2 aa 1 to C-terminus.
Constituents: PBS, 0.1% BSA
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Western blot analysis of varying levels of Recombinant human IL-2 protein using ab271228 at 0.1 μg/ml.
Used in conjunction with compatible secondary reagents the detection limit for recombinant IL-2 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Lane ng/lane
1 Marker
2 250
3 125
4 62.5
5 31.25
6 15.625
7 7.8
8 3.9
9 1.95
10 0.975
11 0.4875
12 0.24
All lanes: Western blot - Biotin Anti-IL-2 antibody (ab271228)
Performed under reducing conditions.
Predicted band size: 17 kDa
Human hIL-2 was detected by sandwich ELISA (using 100μl/well) using a concentration of 0.25-1.0 μg/ml of ab271228. This antibody in conjunction with an appropriate capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant hIL-2 protein.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com